Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Developing transformative, best-in-class neuropsychiatric therapies
Develops novel antibody treatments for immunological and inflammatory disorders
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
Develops novel therapies to reduce the burden of neurodegenerative diseases
Developing a next-generation pertussis vaccine candidate BPZE1
Develops precision immunoregulatory medicines based on tissue Treg biology
Develops small molecule drugs for historically challenging drug targets
Develops bispecific antibody CLD-423 for inflammatory bowel disease
Develops medicines targeting historically undruggable protein targets in cancer